Brief: Moonlake Immunotherapeutics Starts Phase 2 Trial Of NanobodySonelokimab In Patients With Moderate-To-Severe Hidradenitis Suppurativa
12/05/2022 12:06
May 12 (Reuters) - Helix Acquisition Corp MLTX.O :
* MOONLAKE IMMUNOTHERAPEUTICS STARTS PHASE 2 TRIAL OF
NANOBODY®SONELOKIMAB IN PATIENTS WITH MODERATE-TO-SEVERE
HIDRADENITIS SUPPURATIVA
Source text for Eikon: ID:nGNXbH1tzP
Further company coverage: MLTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial